The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.
Pharmacies and pharmacists can help the rapid deployment of COVID-19 vaccines when available, NACDS said.
IW-3718, an investigational adjunct therapy to proton pump inhibitors for refractory GERD, showed favorable results in reducing heartburn severity and other symptoms.
An analysis found that US patients with COVID-19 are experiencing longer hospital stays and higher rates of ICU admissions than patients in China.
Can coronavirus-related stress cause shingles?
FDA OKs Ticagrelor Indication to Reduce Risk of First Heart Attack, Stroke in Patients With High-Risk CAD
This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.
Officials with the FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.
Apotex Corp is voluntarily recalling all lots of metformin hydrochloride extended-release tablets, USP 500 mg, within expiry to retail level.
ASCO20 Virtual: Pembrolizumab Doubles Progression-Free Survival for Certain Advanced Colorectal Cancer Types
The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.